---
figid: PMC6349439__oncotarget-10-84-g001
figlink: /pmc/articles/PMC6349439/figure/F1/
number: F1
caption: Off-target resistance mechanisms generally involve activation of bypass signalling
  pathways (blue boxes) which could be downstream of the oncogenic driver pathway
  (red box) or a parallel signalling pathway that could sustain survival and proliferation
  of tumor cells even in the presence of the TKI. This off-target resistance could
  be overcome by using a combination of lorlatinib treatment with other inhibitors
  such as pictilisib (PI3K inhibitor), trametinib (MAPK inhibitor), erlotinib (EGFR
  inhibitor) or afatinib (HER4 inhibitor) based on the involvement of the respective
  signalling pathways.
pmcid: PMC6349439
papertitle: We shall overcome (drug resistance) some day.
reftext: Geeta G. Sharma, et al. Oncotarget. 2019 Jan 4;10(2):84-85.
pmc_ranked_result_index: '11833'
pathway_score: 0.9499436
filename: oncotarget-10-84-g001.jpg
figtitle: We shall overcome (drug resistance) some day
year: '2019'
organisms:
- Homo sapiens
ndex: c67a048b-de95-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6349439__oncotarget-10-84-g001.html
  '@type': Dataset
  description: Off-target resistance mechanisms generally involve activation of bypass
    signalling pathways (blue boxes) which could be downstream of the oncogenic driver
    pathway (red box) or a parallel signalling pathway that could sustain survival
    and proliferation of tumor cells even in the presence of the TKI. This off-target
    resistance could be overcome by using a combination of lorlatinib treatment with
    other inhibitors such as pictilisib (PI3K inhibitor), trametinib (MAPK inhibitor),
    erlotinib (EGFR inhibitor) or afatinib (HER4 inhibitor) based on the involvement
    of the respective signalling pathways.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CG
  - MAPK8
  - MAPK3
  - PIK3CD
  - MAPK11
  - MAPK1
  - PIK3R6
  - STAT3
  - MAPK12
  - MAPK14
  - PIK3R3
  - MAPK10
  - ERBB4
  - ALK
  - MAPK9
  - PIK3CB
  - PIK3R5
  - EGFR
  - PIK3CA
  - PIK3R4
  - MAPK13
  - Horlatinib
  - trametinib
  - erlotinib
  - afatinib
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: EGFR/HER4
  symbol: HER4
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB4
  entrez: '2066'
- word: ALK
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: EGFR/HER4
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
chemicals:
- word: Horlatinib
  source: ''
  identifier: ''
- word: trametinib
  source: MESH
  identifier: C560077
- word: erlotinib
  source: MESH
  identifier: C400278
- word: afatinib
  source: MESH
  identifier: C522924
diseases: []
figid_alias: PMC6349439__F1
redirect_from: /figures/PMC6349439__F1
figtype: Figure
---
